Teprotumumab’s mechanism of action in patients with Thyroid Eye Disease has not been fully characterized. Teprotumumab binds to IGF-1R and blocks its activation and signaling.
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| TEPEZZA Powder for solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Teprotumumab is an active ingredient of these brands:
United States (US)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.